Use this link for webcast:lundbeck.eventcdn.net/20190916/ Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming migraine treatment through the discovery, development and commercialization of innovative therapeutic antibodies. Alder`s lead candidate, eptinezumab, is an infusion-administered monoclonal antibody (mAb) that inhibits the calcitonin-related peptide-gene (PGR) to prevent migraine. If approved by the U.S. Food and Drug Administration, it will be the first quarterly anti-CGRP anti-infusion therapy to prevent migraine. Alder is also developing ALD1910, a preclinical mAb that inhibits polypeptide-38 (PACAP-38), which activates the pituitary glandnnylatecyclase, to prevent migraine. For more information, see www.alderbio.com. You can also send questions to firstname.lastname@example.org. Non-negotiable CVRs are paid following the approval by the European Commission of an “application for authorisation” in the European Union under the centralised procedure. The TRC`s terms of payment reflect the parties` compliance with the distribution of the potential economic benefits of such an authorization. It is not possible to guarantee that such authorisation will be granted or that a conditional payment will be made. If options have been issued to you under a grant agreement, the exercise price of the applicable options is the price indicated in the grant agreement for each of those options. The offer to purchase (the Offer) on the current common shares of Alder, referred to in this press release of the Company, has not yet commenced.
The description contained in this communication does not constitute an offer to purchase, an invitation to issue an offer to sell securities, or a substitute for the offer documents that Lundbeck and the buyer will submit to the United States. Securities and Exchange Commission (sec). The invitation and offer to purchase the common shares of Alder are made only in connection with an offer to purchase and related supplies. At the time of commencement of the Offer, Lundbeck will file an offer statement in accordance with Schedule TO and, thereafter, Alder will file with the SEC an invitation/recommendation statement pursuant to Annex 14D-9 regarding the Offer. . . .